CD274 and cancer: In this context, Shafqat et al. reported that 45/157 (28.7%) patients with various types of cancer who were treated with anti-PD-1/PD-L1 MAbs developed IRAEs, predominantly of endocrine origin, 21 of whom were treated with systemic corticosteroids (57).